344 related articles for article (PubMed ID: 7847840)
21. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
Fujimoto S
Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
[TBL] [Abstract][Full Text] [Related]
22. Decreased sensitivity of multidrug-resistant tumor cells to cisplatin is correlated with sorcin gene co-amplification.
Demidova NS; Ilyinskaya GV; Shiryaeva OA; Chernova OB; Goncharova SA; Kopnin BP
Neoplasma; 1995; 42(4):195-201. PubMed ID: 7659186
[TBL] [Abstract][Full Text] [Related]
23. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
24. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB
Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205
[TBL] [Abstract][Full Text] [Related]
26. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
27. Acquired vs innate multidrug resistance and the effect of calcium channel blockers.
Tsuruo T
Prog Clin Biol Res; 1986; 223():203-16. PubMed ID: 3468516
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
29. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.
Tsuruo T; Iida H; Kitatani Y; Yokota K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Oct; 44(10):4303-7. PubMed ID: 6467192
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
31. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42 degrees C).
Juvekar AS; Chitnis MP
Neoplasma; 1991; 38(2):207-11. PubMed ID: 2041579
[TBL] [Abstract][Full Text] [Related]
32. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
Wu L; Smythe AM; Stinson SF; Mullendore LA; Monks A; Scudiero DA; Paull KD; Koutsoukos AD; Rubinstein LV; Boyd MR
Cancer Res; 1992 Jun; 52(11):3029-34. PubMed ID: 1350507
[TBL] [Abstract][Full Text] [Related]
33. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
[TBL] [Abstract][Full Text] [Related]
34. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.
Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Jun; 43(6):2905-10. PubMed ID: 6850602
[TBL] [Abstract][Full Text] [Related]
35. [Gene amplification in murine leukemia cells with multiple drug resistance acquired in vivo].
Demidova NS; Goncharova SA; Chernova OB; Kopnin BP; Gudkov AV
Genetika; 1987 Oct; 23(10):1797-806. PubMed ID: 3692152
[TBL] [Abstract][Full Text] [Related]
36. Establishment of cross-resistance profiles for new agents.
Schabel FM; Skipper HE; Trader MW; Laster WR; Griswold DP; Corbett TH
Cancer Treat Rep; 1983 Oct; 67(10):905-22. PubMed ID: 6354439
[TBL] [Abstract][Full Text] [Related]
37. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT
Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539
[TBL] [Abstract][Full Text] [Related]
38. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
[TBL] [Abstract][Full Text] [Related]
39. Development of a mitoxantrone-resistant P 388 in vivo: approaches to overcome resistance.
Fichtner I; Becker M; Lemm M; Winterfeld G
Oncology; 1990; 47(6):508-15. PubMed ID: 1700851
[TBL] [Abstract][Full Text] [Related]
40. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.
Inaba M; Johnson RK
Cancer Res; 1977 Dec; 37(12):4629-34. PubMed ID: 922743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]